Retatrutide as the next step after the GIP and GLP-1 dual agonist

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The GIP and GLP-1 dual agonist established that adding GIP receptor activity to a GLP-1 receptor agonist improved on GLP-1 agonism alone. Retatrutide carries that forward — a GIP-based backbone with GLP-1 activity — and adds glucagon receptor activity. The discovery paper presents it as a deliberate extension of the dual design.

What the dual agonist showed

That GIP receptor agonism, long dismissed because of blunted GIP responsiveness in type 2 diabetes, contributed to glycaemic and weight outcomes when combined with GLP-1 receptor agonism. That finding, confirmed in large phase 3 trials, changed the field and made a triple agonist a reasonable next question.

It also established the engineering approach: a single modified peptide engaging more than one receptor, with a fatty-acid chain for duration.

What retatrutide inherits and adds

The GIP-derived backbone, the acylation strategy and the long-duration pharmacokinetic target are inherited. The additions are glucagon receptor activity and a deliberately reduced relative potency at the GLP-1 receptor. The discovery paper is explicit that the molecule was designed with the dual agonist as its reference.

The lineage is a matter of record, and it is why the two are so often compared despite no trial containing both.

Why the order matters

Each generation was justified by the previous one. Without the dual agonist result, adding glucagon to a GLP-1 agonist alone would have been a different and less supported hypothesis. The triple agonist is therefore not a parallel alternative to the dual one but a step taken because of it.

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What the dual agonist showed?

That GIP receptor agonism, long dismissed because of blunted GIP responsiveness in type 2 diabetes, contributed to glycaemic and weight outcomes when combined with GLP-1 receptor agonism. That finding, confirmed in large phase 3 trials, changed the field and made a triple agonist a reasonable next question.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.